Outcomes in patients with lacrimal gland carcinoma treated with definitive radiotherapy or eye-sparing surgery followed by adjuvant radiotherapy
Autor: | Joseph Tung-Chieh Chang, Ling Yeung, Din-Li Tsan, Wing-Keen Yap, Shih-Ming Huang, Ju-Wen Yang, Yun-Hsuan Lin, Lung-Chien Chen |
---|---|
Rok vydání: | 2020 |
Předmět: |
lcsh:Medical physics. Medical radiology. Nuclear medicine
Adult Male medicine.medical_specialty medicine.medical_treatment lcsh:R895-920 Lacrimal gland Disease Ophthalmologic Surgical Procedures Eye lcsh:RC254-282 03 medical and health sciences Young Adult 0302 clinical medicine Medicine Humans Radiology Nuclear Medicine and imaging Stage (cooking) Radiation Injuries Lacrimal Gland Carcinoma Aged Retrospective Studies Aged 80 and over Chemotherapy Lacrimal Apparatus Diseases Radiotherapy business.industry Orbital tumors Eye Neoplasms Research Cancer Middle Aged medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Combined Modality Therapy Surgery Radiation therapy medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis 030221 ophthalmology & optometry Female Radiotherapy Adjuvant Lacrimal gland carcinoma Orbital exenteration business Adjuvant |
Zdroj: | Radiation Oncology (London, England) Radiation Oncology, Vol 15, Iss 1, Pp 1-10 (2020) |
ISSN: | 1748-717X |
Popis: | Background The optimal treatment for lacrimal gland cancer remains unclear. Eye-preserving surgery, as opposed to exenteration, followed by adjuvant radiotherapy (RT), has recently been reported to deliver satisfactory outcomes, but evidence is sparse. The aim of the present study was to evaluate outcomes in patients with lacrimal gland cancer treated at two tertiary medical centers. Methods We retrospectively examined data from patients with lacrimal gland cancer who had received eye-preserving surgical treatment followed by adjuvant RT with or without chemotherapy, or (if the tumor was inoperable) needle biopsy with definitive RT with or without chemotherapy. Baseline clinical and pathological characteristics were considered. Outcomes of interest included post-treatment complications, overall survival (OS), locoregional progression-free survival (LPFS), and distant metastasis-free survival (DMFS). Results Eighteen patients were included. Two-year OS, LPFS, and DMFS rates were 69.0, 76.7, and 71.4%, respectively. Patients with early-stage (T1–T2) lacrimal gland cancer had significantly better outcomes than those with advanced-stage disease (T3–T4). Two-year OS, LPFS, and DMFS rates were each 100% in patients with disease stages T1–T2, and 37.5, 50, and 37.5%, respectively, in those with disease stages T3–T4 (P Conclusions Eye-sparing surgery with adjuvant RT can achieve satisfactory results in patients with T1–T2 lacrimal gland carcinoma. Disease stage T3 and above was associated with poor outcomes even with post-operative RT, likely due to distant metastasis. Adding neoadjuvant chemotherapy or adjuvant chemotherapy to current treatment strategies might be a suitable choice for this group of patients. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |